|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment显示文摘Estimates of people suffering from overweight (one billion) and obesity (300 million) are increasing. The accumulation of triglycerides in the liver, in the absence of excess alcohol intake, has been described in the early sixties. It was not until 1980, however, that Ludwig et al named this condition nonalcoholic steatohepatitis (NASH). Subsequently, nonalcoholic fatty liver disease (NAFLD) has been used as a general name for conditions ranging from simple steatosis through steatohepatitis to end-stage liver disease (cirrhosis). Many studies have demonstrated the significant correlation with obesity and insulin resistance. Other studies have revealed a signifi- cant correlation between hepatic steatosis, cardiovascu- lar disease and increased intima-media thickness. WHO estimated that at least two million patients will develop cirrhosis due to hepatic steatosis in the years to come. Longitudinal cohort studies have demonstrated that those patients with cirrhosis have a similar risk to devel- op hepatocellular carcinoma as those with other causes of cirrhosis. Taken all together, NAFLD has become the third most important indication for liver transplantation. There- fore, training programmes in internal medicine, gastroen- terology and hepatology should stress the importance of diagnosing this entity and treat properly those at risk for developing complications of portal hypertension and con- comittant cardiovascular disease. This review will focus on the clinical characteristics, pathophysiology, imaging tech- niques and the readily available therapeutic options. | Tim CMA Schreuder Bart J Verwer Carin MJ van Nieuwkerk Chris JJ Mulder | 2008 | World Journal of Gastroenterology2008，14，16： | 35 |
| 2 | IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treat- ment of Cancer Brain Tumor Group显示文摘 | van den Bent M J Dubbink HJ Marie Y Brandes AA Taphoorn MJ Wesseling P Frenay M Tijssen CC Lacombe D ldbaih A van Marion R Kros JM Dinjens WN Gorlia T. Sanson M. | 2010 | 中国神经肿瘤杂志2010，8，1： | 22 |
| 3 | Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno-or squamous cell carcinoma显示文摘AIM:To determine whether-1195 A→G and/or-765 G→C polymorphisms in Cyclooxygenase-2(COX-2 ) may have a risk modifying effect on the development of esophageal carcinoma in a Dutch Caucasian population.METHODS:Two study groups were recruited, 252 patients with esophageal carcinoma and 240 healthy controls, matched for race, age, gender and recruiting area.DNA was isolated from whole blood and used for genotyping.PCR products were digested with restriction enzymes and products were analyzed by agarose gel electrophoresis.Odds ratios(OR) and 95% confldence intervals(CI) were estimated.RESULTS:The distribution of the-1195 A→G polymorphism was signif icantly different in esophageal cancer patients compared to controls.The-1195 GG genotype resulted in a higher risk of developing esophageal adenocarcinoma(OR = 3.85, 95% CI:1.45-10.3) compared with the-1195 AA genotype as a reference.The-765 G→C genotype distribution was not different between the two groups.The GG/ GG haplotype was present more often in esophageal adenocarcinoma patients than in controls(OR = 3.45, 95% CI:1.24-9.58;with AG/AG as a reference).The same trends were observed in patients with squamous cell carcinomas, however, the results did not reach statistical signif icance.CONCLUSION:Presence of the COX-2-1195 GG genotype and of the GG/GG haplotype may result in a higher risk of developing esophageal carcinoma. | Jón O Kristinsson Paul van Westerveld Rene HM te Morsche Hennie MJ Roelofs T Wobbes Ben JM Witteman Adriaan CITL Tan Martijn GH van Oijen Jan BMJ Jansen Wilbert HM Peters | 2009 | World Journal of Gastroenterology2009，15，28： | 11 |
| 4 | COX-2 polymorphisms-765G→C and-1195A→G and colorectal cancer risk显示文摘AIM:To determine the possible modulating effect of the COX-2 polymorphisms,-765G→C and-1195A→G, on the risk of colorectal cancer(CRC)in a Dutch population. METHODS:This case-control study includes 326 patients with CRC and 369 age-and gender-matched controls.Genotypes of the COX-2 polymorphisms -765G→C and-1195A→G were determined by polymerase chain reaction-based restriction fragment length polymorphism.COX-2 genotypes and haplotypes were analyzed and odds ratios with 95%confi- dence intervals were estimated by logistic regression. RESULTS:The-765GG genotype was associated with an increased risk of developing CRC(OR,1.45; 95%CI,1.03-2.04).No significant difference was observed in the genotype distribution of the-1195A→ G polymorphism between patients and controls.The GG/AC haplotype was present significantly less often in patients than in controls(OR 0.44;95%CI,0.22-0.85). When the AC,AG and GG haplotypes were investigated separately,the AC haplotype showed a tendency to be less frequent in patients than in controls(OR(AG/AC)0.78; 95%CI,0.57-1.06). CONCLUSION:The-765GG genotype is associatedwith an increased risk of developing CRC and the GG/ AC haplotype seems to protect against CRC.These findings suggest a modulating role for the COX-2 polymorphisms-765G→C and-1195A→G in the development of CRC in a Dutch population. | Juliёt H Hoff Rene HM te Morsche Hennie MJ Roelofs Elise MJ van der Logt Fokko M Nagengast Wilbert HM Peters | 2009 | World Journal of Gastroenterology2009，15，36： | 6 |
| 5 | Assessment of oxidative stress in chronic pancreatitis patients显示文摘AIM: To assess the levels of antioxidant capacity and oxidative damage in blood of chronic pancreatitis (CP) patients in comparison with those in healthy control sub- jects, by using several different analytical techniques. METHODS: Thirty-five CP patients and 35 healthy con- trol subjects were investigated prospectively with re- spect to plasma levels of thiols, ferric reducing ability of plasma (FRAP, i.e. antioxidant capacity), levels of protein carbonyls and thiobarbituric acid reactive substances (TBARS). Additionally, we evaluated the production of reactive oxygen species (ROS) in whole blood. RESULTS: The antioxidative thiols including cysteine, cysteinylglycine and glutathione were significantly lower in CP patients. In addition, the non-enzymatic antioxi- dant capacity was significantly lower in CP patients, which correlated with the amount of oxidative protein (protein carbonyls) and the extent of lipid damage (TBARS), both were significantly higher in CP patients. The ROS production in whole blood after stimulation with phorbol 12-myritate 13-acetaat, demonstrated a strong tendency to produce more ROS in CP patients. CONCLUSION: Oxidative stress may contribute to the pathogenesis of chronic pancreatitis by decreasing anti- oxidant capacity and increasing oxidative damage in CP patients may be a rationale for intervention with antioxi- dant therapy. | Mariette Verlaan Hennie MJ Roelofs Annie van Schaik Geert JA Wanten Jan BMJ Jansen Wilbert HM Peters Joost PH Drenth | 2006 | World Journal of Gastroenterology2006，12，35： | 3 |
| 6 | Auto immune hepatitis显示文摘To provide an update of the latest trends in epidemiology, clinical course, diagnostics, complications and treatment of auto immune hepatitis(AIH). A search ofthe MEDLINE database was performed using the search terms: 'auto immune hepatitis', 'clinical presentation', 'symptoms', 'signs', 'diagnosis', 'auto antibodies', 'laboratory values', 'serology', 'histopathology', ' h i s t o l o g y ', ' g e n e t i c s ', 'HLA g e n e s ', 'non-HLA genes', 'environment', 'epidemiology', 'prevalence', 'incidence', 'demographics', 'complications', 'HCC', 'PBC', 'PSC', 'corticosteroid', 'therapy', 'treatment', 'alternative treatment'. English-language full-text articles and abstracts were considered. Articles included reviews, meta-analysis, prospective retrospective studies. No publication date restrictions were applied. AIH is an immune meditated progressive inflammatory liver disease that predominantly affects middle-aged females but may affect people of all ages. The clinical spectrum of AIH is wide, ranging from absent or mild symptoms to fulminant hepatic failure. The aetiology of AIH is still unknown, but is believed to occur as the consequence of an aberrant immune response towards an un-known trigger in a genetically susceptible host. In the absence of a gold standard, diagnosis is based on the combination of clinical, biochemical and histopathological criteria. Immunosuppressive treatment has been the cornerstone of treatment since the earliest description of the disease in 1950 by Waldenstr?m. Such treatment is often successful at inducing remission and generally leads to normal life expectancy. Nevertheless, there remain significant areas of unmet aetiological a clinical needs including fundamental insight in disease pathogenesis, optimal therapy, duration of treatment and treatment alternatives in those patients unresponsive to standard treatment regimens. | nicole mf van gerven ynto s de boer chris jj mulder carin mj van nieuwkerk gerd bouma | 2016 | World Journal of Gastroenterology2016，22，19： | 3 |
| 7 | Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review显示文摘AIM:To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS:A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated.To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS:Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI:67%-73%) and 59% in RA (95%CI:58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI:1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI:1.3-1.52) and 1.13 (95%CI:1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION:One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence. | Herma H Fidder Maartje MJ Singendonk Mike van der Have Bas Oldenburg Martijn GH van Oijen | 2013 | World Journal of Gastroenterology2013，19，27： | 2 |
| 8 | Diagnosis,treatment and prognosis ofinternal mammary lymph node recurronce in breast cancer patients显示文摘 | Cranenbroek S van der Sangen MJ Kuijt GP | 2005 | Breast Cancer ResTreat2005，89，3： | 1 |
| 9 | Circleof Willis collateral flowinvestigated by magnetic resonance an-giography显示文摘 | Harkamp MJ van Der Grond J van Everdingen KJ | 1999 | Stroke1999，30，12： | 1 |
| 10 | Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia : a recta-analysis 显示文摘 | Veldhuyzen van Zanten SJ Jones MJ Verlinden M Talley NJ | 2001 | Am J Gastroenterol2001，96，： | 1 |
| 11 | Radiotherapy plusconcomitant and adjuvant temozolomide for glioblastoma显示文摘 | Stupp R Mason WP van den Bent MJ | 2005 | NEngl J Med2005，352，10： | 1 |
| 12 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma显示文摘 | STUPP R MASON WP VAN DEN BENT MJ | 2005 | N Engl J Med2005，352，10： | 1 |
| 13 | Optimal left ventricu- lar lead position assessed with phase analysis on gated myocardial perfusion SPECT显示文摘 | Boogers MJ Chen J Van Bommel RJ | 2011 | Eur J Nucl Med Mol Imaging2011，38，2： | 1 |
| 14 | Development andqualification of the parallel line model for the estimation of humaninfluenza haemagglutinin content using the single radial immunod-iffusion assay显示文摘 | Van Kessel G Geels MJ De Weerd S | 2012 | Vaccine2012，30，2： | 1 |
| 15 | Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitisB using HBsAg and HBV DNA levels 显示文摘 | Rijckborst V Hansen BE Cakaloglu Y Ferenci P Tabak F Akdogan M Simon K Akarca US Flisiak R Verhey E Van Vuuren AJ Boucher CA ter Borg MJ Janssen HL | 2010 | Hepatology2010，52，2： | 1 |
| 16 | A gene-expression signature as a predictor of survival in breast cancer显示文摘 | van de Vijver MJ He YD van't Veer LJ | 2002 | N Engl j Med2002，347，25： | 1 |
| 17 | Mouse strain differences in autonomic responses to stress显示文摘 | van Bogaert MJ Groenink L Oosting RS | 2006 | Genes Brain Behav2006，5，2： | 1 |
| 18 | Reliability and validity of the visual analogue scale for fear of falling in older persons显示文摘 | Scheffer AC Schurmans MJ van Dijk N | | 0，，11： | 1 |
| 19 | Prospective evaluation of psychosocial adaption to stoma surgery: the role of self-efficacy显示文摘 | BEKKERS MJ VAN KNIPPENBERG FC VAN DEN BORNE HW | 1996 | Psychosom Med1996，58，2： | 1 |
| 20 | Prospectiveeva1uation of psychosocia1 adaption to stom a surgery:the role of self-efficacy显示文摘 | Bekkers MJ Van Knippenberg FC Van Den Borne HW | 1996 | Psychosom Med1996，58，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员